<p>Epoetin Beta is indicated for:</p>

<ul>
	<li>Treatment of symptomatic anemia associated with chronic kidney disease (CKD) in patients on dialysis.</li>
	<li>Treatment of symptomatic renal anemia in patients not yet undergoing dialysis.</li>
	<li>Prevention of anemia of prematurity in infants with a birth weight of 750 to 1500 g and a gestational age of less than 34 weeks.</li>
	<li>Treatment of symptomatic anemia in adult patients with non-myeloid malignancies receiving chemotherapy.</li>
	<li>Increasing the yield of autologous blood from patients in a pre-donation programme.</li>
</ul>

<p>Its use in this indication must be balanced against the reported increased risk of thromboembolic events. Treatment should only be given to patients with moderate anemia (Hb 10&ndash;13 g/dl [6.21&ndash;8.07 mmol/l], no iron deficiency) if blood conserving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males).</p>